BELLEVUE, Wash., Jan. 27 /PRNewswire/ -- Light Sciences Oncology, Inc. (LSO) today announced the election of former Commissioner of the FDA, Frank Young, M.D., Ph.D., to a newly created seat on its board of directors.
Dr. Young has held positions in clinical practice, academia and government, including Commissioner of the FDA from 1984 to 1989. He has also served as a corporate, venture finance, and regulatory consultant. He was the U.S. Representative to the Executive Committee of the World Health Organization, as well as Dean of the School of Medicine and Dentistry, Director of the Medical Center, and Vice President for Health Affairs at the University of Rochester in New York. Dr. Young is presently a partner at Essex Woodlands Health Ventures, an investor in Light Sciences Oncology. He received his medical doctorate from Upstate Medical University, New York, and a Ph.D. from Case Western Reserve University. His internship and residency in Pathology was at University Hospitals in Cleveland, Ohio.
“Dr. Young’s unique experience and perspective on industry and regulatory issues will be particularly useful as we approach a potential NDA submission in 2009 for Light Infusion Therapy as a treatment for primary liver cancer, and in 2010 as a treatment for metastatic colorectal cancer,” said Llew Keltner, M.D., Ph.D., president and CEO of Light Sciences Oncology.
“I am especially excited to join the Light Sciences Oncology board of directors at this pivotal time for the company and its products under development,” added Dr. Young. “I am looking forward to sharing my experience over a long career to help LSO reach its goal of providing a revolutionary therapy to cancer patients.”
About Light Sciences Oncology
Light Sciences Oncology (LSO) is the developer of Light Infusion Therapy(TM) (Litx(TM)), an innovative light-activated drug treatment for solid tumors and other conditions. The drug treatment is activated by a palm-sized, single-use, disposable unit designed to provide easy use for physicians and tolerable, effective, and repeatable treatments for patients. LSO has completed enrollment of patients in a Phase 3 trial of Litx in hepatocellular carcinoma (HCC) and is currently enrolling patients in a Phase 3 trial for metastatic colorectal cancer (MCRC). LSO has also completed a Phase 1/2 trial and has initiated a Phase 2a trial in benign prostatic hyperplasia (BPH), or enlargement of the prostate. LSO’s development organization oversees engineering, clinical trials, manufacturing, and regulatory/legal affairs. The company has positioned itself for growth with a strong portfolio of intellectual property, innovative applications in development, and an exceptionally capable and efficient team.
Contacts
Website: www.lsoncology.com
Light Infusion Therapy(TM), Litx(TM), and LS11(R) are trademarks of Light Sciences Oncology, Inc.
CONTACT: Robert M. Littauer, Vice President, Chief Financial Officer and
Treasurer, +1-425-957-8900, bobl@lsoncology.com; or Llew Keltner, M.D.,
Ph.D., President and CEO, +1-425-957-8900, dr_llew@lsoncology.com
Web site: http://www.lsoncology.com/
